Axsome Therapeutics (AXSM) Net Income towards Common Stockholders (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$64.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 8.63% year-over-year to -$64.5 million; the trailing twelve-month figure through Mar 2026 stood at -$188.4 million (up 32.31% YoY), and the FY2025 full-year result was -$183.2 million, up 36.21% from the prior year.
• Net Income towards Common Stockholders declined to -$64.5 million in Q1 2026, from -$28.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$11.2 million in Q1 2023 to a low of -$98.6 million in Q4 2023.
• A 5-year average of -$56.6 million and a median of -$61.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 81.04% in 2022 and plunged 508.27% in 2024, its largest moves.
• Tracing AXSM's Net Income towards Common Stockholders over 5 years: stood at -$61.2 million in 2022, then tumbled by 61.06% to -$98.6 million in 2023, then gained by 24.05% to -$74.9 million in 2024, then soared by 61.78% to -$28.6 million in 2025, then tumbled by 125.43% to -$64.5 million in 2026.
• Business Quant data shows AXSM's Net Income towards Common Stockholders at -$64.5 million in Q1 2026, -$28.6 million in Q4 2025, and -$47.2 million in Q3 2025.